Hao-Tu Zhu1,2, Rong-Bin Liu1,2, Ya-Yong Liang3, Abdulbaqi M E Hasan1,2, Hai-Yun Wang1,2, Qiong Shao1,2, Zi-Chen Zhang1,2, Jing Wang1,2, Cai-Yun He1,2, Fang Wang1,2, Jian-Yong Shao1,2. 1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. 2. Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China. 3. Department of paediatrics, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Abstract
BACKGROUND & AIMS: The discovery of effective and reliable biomarkers to detect hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC) at an early stage may improve the survival of HCC. The aim of this study was to establish serum microRNA (miRNA) profiles as diagnostic biomarkers for HBV-positive HCC. METHODS: We used deep sequencing to screen serum miRNAs in a discovery cohort (n=100). Quantitative polymerase chain reaction (qPCR) assays were then applied to evaluate the expression of selected miRNAs. A diagnostic 2-miRNA panel was established by a logistic regression model using a training cohort (n=182). The predicted probability of being detected as HCC was used to construct the receiver operating characteristic (ROC) curve. Area under the ROC curve (AUC) was used to assess the diagnostic performance of the selected miRNA panel. RESULTS: The predicted probability of being detected as HCC by the 2-miRNA panel was calculated by: logit P=-2.988 + 1.299 × miR-27b-3p + 1.245 × miR-192-5p. These results were further confirmed in a validation cohort (n=246).The miRNA panel provided a high diagnostic accuracy of HCC (AUC=0.842, P<.0001 for training set; AUC=0.836, P<.0001 for validation set respectively). In addition, the miRNA panel showed better prediction of HCC diagnosis than did alpha-foetoprotein (AFP). The miRNA panel also differentiated HCC from healthy (AUC=0.823, P<.0001), and cirrhosis patients (AUC=0.859, P<.0001) respectively. CONCLUSIONS: Differentially expressed serum miRNAs may have considerable clinical value in HCC diagnosis, and be particularly helpful for AFP-negative HCC.
BACKGROUND & AIMS: The discovery of effective and reliable biomarkers to detect hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC) at an early stage may improve the survival of HCC. The aim of this study was to establish serum microRNA (miRNA) profiles as diagnostic biomarkers for HBV-positive HCC. METHODS: We used deep sequencing to screen serum miRNAs in a discovery cohort (n=100). Quantitative polymerase chain reaction (qPCR) assays were then applied to evaluate the expression of selected miRNAs. A diagnostic 2-miRNA panel was established by a logistic regression model using a training cohort (n=182). The predicted probability of being detected as HCC was used to construct the receiver operating characteristic (ROC) curve. Area under the ROC curve (AUC) was used to assess the diagnostic performance of the selected miRNA panel. RESULTS: The predicted probability of being detected as HCC by the 2-miRNA panel was calculated by: logit P=-2.988 + 1.299 × miR-27b-3p + 1.245 × miR-192-5p. These results were further confirmed in a validation cohort (n=246).The miRNA panel provided a high diagnostic accuracy of HCC (AUC=0.842, P<.0001 for training set; AUC=0.836, P<.0001 for validation set respectively). In addition, the miRNA panel showed better prediction of HCC diagnosis than did alpha-foetoprotein (AFP). The miRNA panel also differentiated HCC from healthy (AUC=0.823, P<.0001), and cirrhosispatients (AUC=0.859, P<.0001) respectively. CONCLUSIONS: Differentially expressed serum miRNAs may have considerable clinical value in HCC diagnosis, and be particularly helpful for AFP-negative HCC.
Authors: Martina Faraldi; Laura Gerosa; Marta Gomarasca; Veronica Sansoni; Silvia Perego; Ewa Ziemann; Giuseppe Banfi; Giovanni Lombardi Journal: Diagnostics (Basel) Date: 2021-04-30
Authors: Xiao-Ran Long; Yao-Jun Zhang; Mei-Yin Zhang; Keng Chen; X F Steven Zheng; Hui-Yun Wang Journal: Aging (Albany NY) Date: 2017-06-27 Impact factor: 5.682
Authors: Sara Nunes; Icaro Bonyek Silva; Mariana Rosa Ampuero; Almério Libório Lopes de Noronha; Lígia Correia Lima de Souza; Thaizza Cavalcante Correia; Ricardo Khouri; Viviane Sampaio Boaventura; Aldina Barral; Pablo Ivan Pereira Ramos; Cláudia Brodskyn; Pablo Rafael Silveira Oliveira; Natalia Machado Tavares Journal: Front Immunol Date: 2018-04-04 Impact factor: 7.561